Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study

OBJECTIVE: Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan City, China, coronavirus disease 2019 (COVID-19) has become a global pandemic. However, no special therapeutic drugs have been identified for COVID-19. The aim of this study was to search for drugs...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Pharmacol
Egile Nagusiak: Fang, Jie, Li, Hui, Du, Wei, Yu, Ping, Guan, Ying-Yun, Ma, Shi-Yu, Liu, Dong, Chen, Wei, Shi, Guo-Chao, Bian, Xiao-Lan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2020
Gaiak:
Pharmacology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7530276/
https://ncbi.nlm.nih.gov/pubmed/33071781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.560209
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak